Dandelion Health develops a multimodal clinical AI platform intended to inform drug development and redesign clinical trial design using high-fidelity longitudinal clinical data. The company positions its platform to better characterize pre-disease windows and patient trajectories so trials are built against current clinical realities rather than outdated disease definitions. Leadership mentioned in the announcement includes Elliott Green and Niyum Gandhi, and the company has attracted investors with healthcare and scientific expertise. Financially, the company completed a $14 million Series A led by new investors Healthier Capital and Colle Capital alongside returning investors Primary Venture Partners, Moxxie Ventures, and Convergent Ventures. Dandelion says the new capital will be applied to continue developing its clinical-AI capabilities and expanding its platform's use in life sciences and AI development. The article does not disclose revenue, user, or other operating metrics.

Total raised

$30M

Funding rounds

2

Latest round

Series A

Latest activity

May 2026